

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**  
**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT**  
**HUMORAL AND CELLULAR IMMUNITY OF THE MRNA RSV**  
**VACCINE WERE SIGNIFICANTLY HIGHER THAN THOSE OF**  
**INTERNATIONALLY MARKETED PRODUCTS**  
**APPLICATION FOR CLINICAL TRIAL IN THE U.S.**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA RSV (respiratory syncytial virus) vaccines has been submitted to the U.S. Food and Drug Administration (“**FDA**”) recently.

In preclinical animal tests, results from a third-party testing unit showed that the specific IgG antibody titers, live-virus neutralizing antibody potency and specific T-cell immunity of the Group’s mRNA RSV vaccine were significantly higher than those of the internationally marketed mRNA RSV control vaccine.

RSV, a common respiratory tract infection pathogen, is highly contagious and widely prevalent worldwide. RSV infection is an important cause of death of infants under one year old and also an important factor in the death of respiratory tract infections in the elderly. Meanwhile, people who have been infected with RSV previously are still at risk of being reinfected with RSV. At present, there is no approved antiviral drug specifically for RSV that is available for clinical use worldwide, and vaccination for active immune prophylaxis is an effective means to avoid severe RSV infection. No RSV vaccine has been approved for marketing in China. In 2023, the global sales of RSV vaccines reached US\$2.46 billion. According to the forecast of China Insights Industry Consultancy Limited, an industry consultant, it is expected that the global market size of RSV vaccines will reach approximately US\$16.7 billion by 2030. This product, if progressing well, will accelerate the pace of internationalization of the Group and bring considerable performance growth to the Group.

The Group is one of the enterprises that takes the lead in developing mRNA vaccine products in China, and also one of the first batch of domestic vaccine enterprises that has obtained an independent patent for mRNA technology. The Group has a mature mRNA vaccine research and development system. Meantime, the Group has established a sound quality management system for mRNA vaccines and a commercial-scale production workshop in line with GMP standards, and the mRNA technology platform have been verified by tens of thousands of human clinical trials data of mRNA vaccine products. The Group has now smoothed the whole life cycle process such as the research, development and production of mRNA vaccines, allowing for rapid achievement of the industrialization of mRNA vaccine products after obtaining clinical approval and accelerating the commercialization process of vaccine products.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, February 5, 2025

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.*